Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression

Molecular Medicine Reports

Volumn 6, Issue 6, 2012, Pages 1267-1270

  Sun, Xiao Dong ^a   Liu, Xing E ^b   Huang, Dong Sheng ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG HOSPITAL   (China)

Author keywords

Breast cancer; Curcumin; EGFR; Triple negative

Indexed keywords

CURCUMIN; MITOGEN ACTIVATED PROTEIN KINASE 3; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL PROLIFERATION; FLOW CYTOMETRY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RECEPTORS, ESTROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS;

CURCUMA LONGA;

EID: 84868577510     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1103     Document Type: Article

References (23)

1. Goel A and Aggarwal BB: Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62: 919-930, 2010.
2. Basnet P and Skalko-Basnet N: Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16: 4567-4598, 2011.
3. Siziopikou KP, Ariga R, Proussaloglou KE, et al: The challenging estrogen receptor-negative/progesterone receptor-negative/ HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J 12: 360-362, 2006. (Pubitemid 43989982)
4. De Ruijter TC, Veeck J, de Hoon JP, et al: Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137: 183-192, 2011.
5. Thike AA, Cheok PY, Jara-Lazaro AR, et al: Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23: 123-133, 2010.
6. Tan DS, Marchió C, Jones RL, et al: Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111: 27-44, 2008. (Pubitemid 352009225)
7. Eralp Y, Derin D, Ozluk Y, et al: MAPK overexprssion is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 19: 669-674, 2008 (Pubitemid 351461036)
8. Wilken R, Veena MS, Wang MB and Srivatsan ES: Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10: 12-31, 2011.
9. Reuter S, Eifes S, Dicato M, et al: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76: 1340-1351, 2008.
10. Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269: 199-225, 2008.
11. Rowe DL, Ozbay T, O'Regan RM and Nahta R: Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer (Auckland) 3: 61-75, 2009.
12. Oiso S, Ikeda R, Nakamura K, et al: Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep 28: 27-32, 2012.
13. Chiu TL and Su CC: Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NFκBp65 expression in breast cancer MDA-MB-231 cells. Int J Mol Med 23: 469-475, 2009.
14. Chakraborty G, Jain S, Kale S, et al: Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Report 1: 641-646, 2008.
15. Cui SX, Qu XJ, Xie YY, et al: Curcumin inhibits telomerase activity in human cancer cell lines. Int J Mol Med 18: 227-231, 2006.
16. Mimeault M and Batra SK: Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med 6: 31, 2011.
17. Hirose H, Ishii H, Mimori K, et al: Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors. Oncol Rep 23: 35-43, 2010.
18. Lee JY, Lee YM, Chang GC, et al: Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS One 6: e23756, 2011.
19. Chadalapaka G, Jutooru I, Burghardt R and Safe S: Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 8: 739-750, 2010.
20. Billar JA, Dueck AC, Stucky CC, et al: Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol 17 (Suppl 3): 384-390, 2010.
21. Sutton LM, Han JS, Molberg KH, et al: Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am J Clin Pathol 134: 782-787, 2010.
22. Ueno NT and Zhang D: Targeting EGFR in triple negative breast cancer. J Cancer 2: 324-328, 2011.
23. Sánchez-Muñoz A, Gallego E, de Luque V, et al: Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 10: 136, 2010.